You've just compared two treatment plans for the same frown lines, and the numbers look completely different. One injector quoted 20 units of Botox, while another mentioned 50 units of Dysport. It's reasonable to wonder whether one plan is excessive, but the unit counts alone don't answer that question.
Botox and Dysport use different potency measurements. Their units are tied to each product's own manufacturing and assay methods, so one Botox unit does not equal one Dysport unit. The practical question isn't which plan has fewer units. It's how the injector arrived at the dose, which ratio they use, and whether that ratio fits your muscles, treatment area, and goals.
Table of Contents
- Why Two Different Unit Numbers for the Same Treatment
- What a Botulinum Toxin Unit Actually Measures
- The Numbers Behind Botox to Dysport Conversion
- Onset, Duration, and Diffusion Compared
- How the Same Patient Gets Different Unit Plans by Area
- How Injectors Build a Treatment Plan Around Units
- Choosing Between Botox and Dysport for Your Goals
Why Two Different Unit Numbers for the Same Treatment
The first point to settle is simple: Botox and Dysport aren't dose-for-dose interchangeable. The FDA labeling for Dysport says its potency units are specific to its preparation and assay method and cannot be compared with or converted into units of other botulinum toxin products. Botox labeling makes the same point about its own biological activity units. The peer-reviewed review of botulinum toxin units likewise describes units as specific to the preparation and assay method.
That's why comparing 20 Botox units with 50 Dysport units as if they were identical currencies creates confusion. The higher Dysport number doesn't automatically mean a stronger or riskier treatment. It reflects a different product-specific scale.

What determines the quoted dose
An injector usually considers several variables before choosing a number:
- The product being used: Botox and Dysport require different unit counts for a similar clinical effect.
- The treatment area: The glabella, forehead, crow's feet, and masseters have different muscle patterns and dosing needs.
- Muscle strength: A patient with forceful brow contraction may need a different plan from someone with mild movement.
- Desired movement: Softening lines while preserving expression calls for a different strategy than maximizing relaxation.
- Injection pattern: Placement, number of injection points, dilution, and the intended spread all influence the plan.
- Treatment history: Your previous product, dose, duration, and response provide useful information for the next visit.
A quote should therefore be understood as a product-specific treatment plan, not as a universal price or dose comparison. The FDA labeling distinction is important because cross-product ratios used in aesthetic practice are clinical estimates, not an official conversion rule.
Practical rule: Ask for the product name, the total dose for each area, and the injector's usual Botox-to-Dysport ratio. A unit number without that context isn't very informative.
The rest of the decision involves more than arithmetic. Conversion ratios explain why the totals change, but onset, duration, diffusion, muscle anatomy, and injector technique determine whether the plan works well for you.
What a Botulinum Toxin Unit Actually Measures
A botulinum toxin unit is a biologic potency measurement, not a measurement of weight, volume, or the amount of liquid in a syringe. It reflects how much activity a preparation produces under a specific laboratory assay. Because manufacturers use different preparations and assay methods, the same number printed on two labels doesn't represent an identical amount of active product.
The assay historically used for botulinum toxin potency is a mouse lethality assay. It estimates the amount of toxin associated with paralysis and death in 50 percent of test subjects, commonly described as an LD50 measurement. That laboratory result creates a product-specific potency unit. It doesn't mean an injector is measuring the physical mass of toxin in the syringe, and it doesn't create a universal currency shared by every brand.
Why the label numbers diverge
Botulinum toxin products can differ in their molecular characteristics, complex sizes, formulations, manufacturing processes, and assay methods. Those differences affect how potency is established before the product reaches clinical use.
The FDA's position is direct. Dysport units cannot be compared to or converted into units from other botulinum toxin products, and Botox labeling says its own units cannot be compared with or converted into another product's units. The FDA Dysport prescribing information documents that labeling position.
That doesn't make clinical comparisons impossible. It means an injector can't substitute the same numerical dose and assume the outcome will match. Published comparative studies can evaluate how products perform at different ratios, while an experienced clinician can use that evidence as a starting point for treatment planning.
What a conversion ratio really means
A ratio such as 2.5 Dysport units to 1 Botox unit is a practical estimate of clinical effect, not a statement that the products contain equivalent units. It's also not a guarantee that every patient, muscle, or indication will respond identically.
This distinction protects patients from a common mistake. A clinic charging or quoting by the unit may make Dysport appear dramatically different from Botox until you account for the fact that more Dysport units are normally used. The more useful comparison is the complete plan for the specific area, including the product, dose, technique, and expected outcome.
The Numbers Behind Botox to Dysport Conversion
In aesthetic practice, the most commonly cited working relationship is roughly 1 Botox unit to 2.5 to 3 Dysport units. The review of botulinum toxin preparations and clinical conversion describes this practical relationship and notes that approved U.S. glabellar doses differ by product, with 20 Botox Cosmetic units and 50 Dysport units serving as labeled reference points.
The math is straightforward:
- 20 Botox units × 2.5 = 50 Dysport units
- 20 Botox units × 3 = 60 Dysport units
So when a patient hears 20 units of Botox from one injector and 50 to 60 units of Dysport from another, the numbers may describe broadly comparable glabellar planning. The clinical effect still depends on placement, muscle strength, dilution, and the injector's technique.

Why the ratio isn't universal
Research has reported broader relationships depending on the indication, study design, assay method, and outcome measured. The literature has included ratios from approximately 2:1 to 4:1, while another review describes reported ranges from roughly 1.7:1 to 5:1. The review discussing variability in reported conversion ratios explains why a single chart can't capture every clinical situation.
A pharmacokinetic paper reported 20 units per nanogram for Botox and 40 units per nanogram for Dysport, yet concluded that 1 Botox unit was roughly equivalent to 3 Dysport units clinically. Later comparative work found similar fields of effect at a 2.0:1 labeled-unit ratio, but greater diffusion-related anhidrotic area for abobotulinumtoxinA at 2.5:1, reinforcing that the dose ratio changes the behavior being measured. These findings are summarized in the PubMed-indexed comparison of Botox and Dysport.
| Ratio, Dysport to Botox | Common clinical use | Botox glabellar dose | Equivalent Dysport dose |
|---|---|---|---|
| 2:1 | Lower end reported in some dosing contexts | 20 units | 40 units |
| 2.5:1 | Common cosmetic starting estimate | 20 units | 50 units |
| 3:1 | Widely used cosmetic estimate | 20 units | 60 units |
| 4:1 | Upper end reported in some studies | 20 units | 80 units |
An injector's personal ratio usually develops from training, product experience, treatment area, and observed patient outcomes. If you're comparing treatment plans or pricing, review the total area-based plan rather than relying on a per-unit figure. ProMD Health Columbia also provides patient education about how much Botox costs, which can help put unit pricing into the broader treatment context.
Onset, Duration, and Diffusion Compared
Unit conversion answers only one part of the patient experience. The practical differences people notice most often involve when movement starts to soften, how long the result remains visible, and how broadly the product spreads from the injection points.
Dysport labeling commonly describes an onset within 2 to 3 days, while Botox is often discussed as beginning around 3 to 5 days. Head-to-head studies have overlapping findings, so these are useful expectations rather than guarantees. Your muscle activity, dose, placement, and individual response still matter.
The three characteristics that affect planning
Onset may matter if you're scheduling treatment around an event. A faster initial response can be useful, but an injector shouldn't compensate for a short timeline by placing an unsuitable dose or treating too close to an important date.
Duration is generally similar for both products, with results commonly discussed as lasting roughly 3 to 4 months. The clinical review of facial wrinkle treatment supports the need to interpret duration through the product, indication, dose, and individual response rather than assuming one toxin always lasts longer.
Diffusion describes how far the treatment effect extends from the injection site. Dysport is often associated with broader spread in comparative discussions, which may help cover a broad muscle such as the forehead. That same characteristic can require more caution near the brow, eyelid, or other areas where unwanted relaxation would be noticeable.
| Characteristic | Botox, onabotulinumtoxinA | Dysport, abobotulinumtoxinA |
|---|---|---|
| Onset | Often discussed around 3 to 5 days | Labeling commonly reports 2 to 3 days |
| Duration | Commonly discussed around 3 to 4 months | Commonly discussed around 3 to 4 months |
| Spread pattern | Often selected when localized placement is important | Often selected when broader spread may be useful |
| Planning concern | Dose and placement must preserve natural movement | Ratio and placement must control unwanted spread |
A product with wider spread isn't automatically better for a large area, and a more localized product isn't automatically safer for every patient. The injector must adjust the dose and injection pattern to the anatomy in front of them.
For practical recovery guidance, patients can review what to expect after Botox, while remembering that aftercare instructions should match the product and technique used during the visit.
How the Same Patient Gets Different Unit Plans by Area
The same person can receive very different Botox and Dysport unit counts across the face because each area has its own muscle size, movement pattern, and tolerance for spread. The ratios below are planning examples, not prescriptions. An injector may adjust them based on anatomy, prior response, and the desired degree of movement.
| Treatment area | Botox units | Dysport units, 2.5:1 | Notes |
|---|---|---|---|
| Glabella | Roughly 20 | Roughly 50 | Common benchmark for frown-line planning |
| Forehead | 10 to 15 | 25 to 40 | Diffusion tolerance and brow position matter |
| Crow's feet | 6 to 12 per side | 15 to 30 per side | Precision is important around the eyes |
| Masseters | 25 to 35 per side | 60 to 90 per side | Muscle bulk and bruxism severity influence dosing |
Four areas, four different decisions
For the glabella, the familiar comparison is roughly 20 Botox units versus 50 Dysport units when using a 2.5:1 ratio. That benchmark can make the two plans look unrelated until the product-specific measurement is considered.
The forehead requires more caution because the frontalis muscle helps lift the brow. Dysport's broader spread may be useful for an even treatment field, but the injector must preserve enough movement to avoid an undesirable brow position. A lower or higher number within the planning range may be appropriate depending on the patient's anatomy.
Around the crow's feet, the muscle is thinner and the margin for unwanted spread is smaller. A plan of 6 to 12 Botox units per side may correspond to 15 to 30 Dysport units per side at the stated ratio, but placement matters at least as much as the arithmetic.
The masseters are different again. These are powerful muscles, and treatment may relate to visible bulk, clenching, or bruxism. A plan of 25 to 35 Botox units per side can translate to 60 to 90 Dysport units per side, but the injector still has to assess the muscle rather than copy a table.
“Equivalent” should mean a comparable treatment objective, not identical unit numbers.
How Injectors Build a Treatment Plan Around Units
A responsible dose starts with an examination, not a conversion chart. The injector evaluates your face at rest, then asks you to raise your brows, frown, squint, smile, clench, or purse your lips. That animation reveals which muscles are driving the lines and how strongly they contract.
The assessment before injection
Muscle strength is only one part of the evaluation. The injector also considers:
- Your baseline anatomy. Brow position, eyelid structure, asymmetry, muscle size, and existing lines affect both dose and placement.
- Your treatment history. The previous product, unit count, injection pattern, onset, duration, and side effects provide a useful record.
- Your goals. Someone who wants softened lines with visible expression needs a different plan from someone seeking maximal relaxation.
- Your risk areas. The brow, eyelid, upper lip, and lower face require careful attention to spread and neighboring muscle function.
- Your schedule. A patient planning around an event may value a predictable timeline, but timing doesn't replace appropriate assessment.
Men often have stronger facial muscles and may require higher unit counts for comparable relaxation, but gender isn't a standalone dosing formula. Muscle bulk, movement, anatomy, and treatment goals are more useful than assumptions based on sex alone.
Documentation makes later visits smarter
The most useful treatment record includes the product, dilution, vial information, units injected into each area, injection sites, date, and observed response. At follow-up, the injector can compare that record with your actual onset, degree of movement, symmetry, and duration.
That process matters when switching products. A change from Botox to Dysport should be treated as re-titration, not as a simple substitution. The injector may begin with a familiar clinical ratio, then refine the next plan based on what your muscles did.
A thoughtful plan also sets expectations for follow-up and explains when an assessment or touch-up may be appropriate. The goal is to build a reliable history for your face, not to chase a universal number.
Choosing Between Botox and Dysport for Your Goals
The right product depends less on the number printed on the vial and more on where you're treating, how quickly you want to see a response, how much spread the area can tolerate, and how familiar your injector is with that product.
A first-time patient seeking controlled treatment near the brow or around the eyes may value a plan that emphasizes precise placement. A patient treating a broad forehead may prefer an approach that uses the product's spread pattern to create even coverage. Neither preference makes one toxin universally superior.
A practical decision framework
| Patient archetype | Primary goal | Botox fit | Dysport fit | Key trade-off |
|---|---|---|---|---|
| First-time patient | Predictable, carefully assessed treatment | May suit a precision-focused plan | May suit a broader treatment strategy | More localized versus broader spread |
| Event-driven patient | Earlier visible softening | Can work when scheduled appropriately | May appeal when faster onset matters | Speed doesn't replace correct timing |
| Patient treating large or powerful areas | Efficient muscle relaxation | Can be planned effectively | Higher unit counts may scale well for the area | Unit totals can look much larger |
| Long-term Botox responder | Consistency | Continuing a successful plan may make sense | Switching may be reasonable if goals change | A new product requires re-titration |
A patient who has responded well to Botox doesn't need to switch because Dysport uses a different unit count. Conversely, someone who wants to try Dysport should ask the injector to explain the ratio, expected spread, and how the new response will be evaluated. Product familiarity matters because technique must change with the product, not just the label.
Before treatment, ask these questions:
- Which ratio do you use for this area?
- Are you quoting units by product or comparing total treatment cost?
- What dilution and vial size are being used?
- What degree of movement are we aiming to preserve?
- When will we evaluate the result?
- How will you document the dose for my next visit?
Budgeting by treatment area is more meaningful than comparing the price of a single unit. A plan that uses fewer Botox units isn't automatically less expensive or more appropriate than a plan using more Dysport units. Review the full treatment recommendation and the clinical reasoning behind it.
For patients in Columbia who want to compare options, ProMD Health Columbia's Dysport information offers product-specific education. ProMD Health Columbia provides both Botox and Dysport, allowing the consultation to focus on anatomy, goals, prior response, and a product-specific dosing plan.
At ProMD Health Columbia, the team can assess your movement patterns, discuss Botox or Dysport unit planning, and tailor treatment to the areas you want to address. Visit ProMD Health Columbia to request a consultation and discuss which product and ratio fit your goals.

